Alterity Therapeutics Future Growth
Future criteria checks 0/6
Alterity Therapeutics's revenue and earnings are forecast to decline at 30.9% and 14.6% per annum respectively.
Key information
-14.6%
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 16.1% |
Revenue growth rate | -30.9% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 06 Mar 2024 |
Recent future growth updates
No updates
Recent updates
Shareholders May Be More Conservative With Alterity Therapeutics Limited's (ASX:ATH) CEO Compensation For Now
Nov 23We're Keeping An Eye On Alterity Therapeutics' (ASX:ATH) Cash Burn Rate
Jun 28Is Alterity Therapeutics (ASX:ATH) In A Good Position To Invest In Growth?
Mar 07We're Hopeful That Alterity Therapeutics (ASX:ATH) Will Use Its Cash Wisely
May 16Here's Why We're Watching Alterity Therapeutics' (ASX:ATH) Cash Burn Situation
Jan 31How Much Is Alterity Therapeutics Limited (ASX:ATH) CEO Getting Paid?
Dec 09Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2026 | 1 | -18 | N/A | N/A | 1 |
6/30/2025 | 2 | -16 | N/A | N/A | 1 |
6/30/2024 | 3 | -13 | N/A | N/A | 1 |
12/31/2023 | 3 | -12 | -15 | -15 | N/A |
9/30/2023 | 4 | -13 | -17 | -17 | N/A |
6/30/2023 | 4 | -14 | -20 | -20 | N/A |
3/31/2023 | 5 | -14 | -17 | -17 | N/A |
12/31/2022 | 5 | -14 | -14 | -14 | N/A |
9/30/2022 | 5 | -14 | -13 | -13 | N/A |
6/30/2022 | 5 | -13 | -12 | -12 | N/A |
3/31/2022 | 5 | -13 | -16 | -16 | N/A |
12/31/2021 | 5 | -13 | -19 | -19 | N/A |
9/30/2021 | 5 | -14 | -18 | -18 | N/A |
6/30/2021 | 4 | -15 | -17 | -17 | N/A |
3/31/2021 | 2 | -16 | -16 | -16 | N/A |
12/31/2020 | 0 | -16 | -14 | -14 | N/A |
9/30/2020 | 0 | -15 | -12 | -12 | N/A |
6/30/2020 | N/A | -13 | -9 | -9 | N/A |
3/31/2020 | 2 | -13 | -9 | -9 | N/A |
12/31/2019 | 4 | -13 | -9 | -9 | N/A |
9/30/2019 | 5 | -12 | -12 | -12 | N/A |
6/30/2019 | 5 | -12 | -14 | -14 | N/A |
3/31/2019 | 5 | -11 | -13 | -13 | N/A |
12/31/2018 | 4 | -10 | -12 | -12 | N/A |
9/30/2018 | 4 | -9 | -9 | -9 | N/A |
6/30/2018 | 3 | -8 | -6 | -6 | N/A |
3/31/2018 | 3 | -8 | -6 | -6 | N/A |
12/31/2017 | 3 | -8 | -6 | -6 | N/A |
9/30/2017 | 3 | -8 | N/A | -6 | N/A |
6/30/2017 | 3 | -8 | N/A | -6 | N/A |
3/31/2017 | 4 | -8 | N/A | -3 | N/A |
12/31/2016 | 4 | -9 | N/A | -1 | N/A |
9/30/2016 | 4 | -8 | N/A | -4 | N/A |
6/30/2016 | 5 | -8 | N/A | -7 | N/A |
3/31/2016 | 5 | -8 | N/A | -9 | N/A |
12/31/2015 | 6 | -7 | N/A | -10 | N/A |
9/30/2015 | 6 | -7 | N/A | -10 | N/A |
6/30/2015 | 6 | -6 | N/A | -11 | N/A |
3/31/2015 | 8 | -6 | N/A | -13 | N/A |
12/31/2014 | 10 | -7 | N/A | -15 | N/A |
9/30/2014 | 9 | -10 | N/A | -14 | N/A |
6/30/2014 | 8 | -13 | N/A | -14 | N/A |
3/31/2014 | 6 | -12 | N/A | -12 | N/A |
12/31/2013 | 4 | -11 | N/A | -11 | N/A |
9/30/2013 | 4 | -10 | N/A | -9 | N/A |
6/30/2013 | 5 | -8 | N/A | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ATH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ATH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ATH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ATH's revenue is expected to decline over the next 3 years (-30.9% per year).
High Growth Revenue: ATH's revenue is forecast to decline over the next 3 years (-30.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ATH's Return on Equity is forecast to be high in 3 years time